Eurofins NTD, LLC, Melville, NY, USA.
Harris Birthright Research Centre for Fetal Medicine, King's College Hospital, London, UK.
Prenat Diagn. 2017 Aug;37(8):802-807. doi: 10.1002/pd.5090. Epub 2017 Jul 18.
The study aims to determine the performance of a five (5) serum marker plus ultrasound screening protocol for T21, T18 and T13.
Specimens from 331 unaffected, 34 T21, 19 T18 and 8 T13 cases were analyzed for free Beta human chorionic gonadotropin, pregnancy-associated plasma protein A, alpha-fetoprotein, placental growth factor and dimeric inhibin A. Gaussian distributions of multiples of the median values were used to estimate modeled false positive and detection rates (DR).
For T21, at a 1/300 risk cut-off, DR of screening with all five serum markers along with nuchal translucency and nasal bone was 98% at a 1.2% false positive rate (FPR). Using a 1/1000 cut-off, the DR was 99% with a 2.6% FPR. For T18/13 with free Beta human chorionic gonadotropin, pregnancy-associated plasma protein A, placental growth factor and nuchal translucency at a 1/150 cut-off, DR was 95% at a 0.5% FPR while at a 1/500 risk cut-off, DR was 97% at a 1.2% FPR.
An expanded conventional screening test can achieve very high DRs with low FPRs. Such screening fits well with proposed contingency protocols utilizing cell-free DNA as a secondary or reflex but also provides the advantages of identification of pregnancies at risk for other adverse outcomes such as early-onset preeclampsia. © 2017 Eurofins NTD, LLC. Prenatal Diagnosis published by John Wiley & Sons, Ltd.
本研究旨在评估一种五项(5)血清标志物联合超声筛查方案在筛查 21 三体、18 三体和 13 三体中的性能。
对 331 例无异常、34 例 21 三体、19 例 18 三体和 8 例 13 三体的标本进行游离β人绒毛膜促性腺激素、妊娠相关血浆蛋白 A、甲胎蛋白、胎盘生长因子和二聚体抑制素 A 的检测。采用中位数倍数的高斯分布来估计模型的假阳性率和检出率(DR)。
对于 21 三体,在 1/300 的风险截断值下,联合颈项透明层和鼻骨超声的五项血清标志物联合筛查的 DR 为 98%,假阳性率(FPR)为 1.2%。使用 1/1000 的截断值,DR 为 99%,FPR 为 2.6%。对于游离β人绒毛膜促性腺激素、妊娠相关血浆蛋白 A、胎盘生长因子和颈项透明层的 1/150 截断值,18/13 三体的 DR 为 95%,FPR 为 0.5%;而在 1/500 的风险截断值下,DR 为 97%,FPR 为 1.2%。
扩展的常规筛查试验可以在低假阳性率下实现非常高的检出率。这种筛查非常适合提议的应急方案,该方案利用游离 DNA 作为二级或反射性检测,同时也提供了识别其他不良结局风险妊娠(如早发性子痫前期)的优势。2017 年欧洲分子遗传实验质控网(EUROFINS NTD)公司。产前诊断由约翰威立父子公司出版。